Nonetheless, considering the previous reports that Tjp1 expression was decreased in glomerular diseases in human and animal models and our findings in the current study, the suppression of Tjp1 could directly aggravate human glomerular disorders, which highlighted Tjp1 as a potential therapeutic target. This evidence concerns the gene TJP1 and glomerular disorder.